This study compared immediate (overnight) and progressive switching to oxcarbazepine monotherapy in patients with partial seizures unsatisfactorily treated with carbamazepine monotherapy. Patients were randomised to either an overnight (n = 140) or a progressive switch (n = 146) from carbamazepine to oxcarbazepine monotherapy at a dose ratio of 1:1.5. The difference between the two switch groups in the mean monthly seizure frequency supported the equivalence of overnight and progressive switching (difference of 0.02 excluding outliers; 95% confidence interval (CI) −0.74, 0.78). Following the switch from carbamazepine to oxcarbazepine, there was a reduction in median monthly seizure frequency in both the overnight group (from 1.5 to 0; P = 0.0005) and the progressive group (from 1.0 to 0.4; P = 0.003). The proportion of seizure-free patients increased from 38 to 51% (P = 0.002) and 39 to 49% (P = −0.01) in the overnight and progressive groups, respectively. In addition, the proportion of patients experiencing no clinically significant adverse events did not differ between the two switch methods (difference of 2.5; 95% CI −4.1, 9.0).
INTRODUCTION
The majority of the estimated 50 million people affected by epilepsy worldwide have a good prognosis, but around 30% do not achieve adequate control of their seizures 1, 2 . The main goal of treatment for epilepsy is to achieve optimum seizure control and tolerability, preferably with a single antiepileptic drug (AED). Monotherapy is suitable for most patients: recent findings suggest that 47% of patients who have not previously received AED treatment become seizure free on their first AED, and a further 13% become seizure free on monotherapy with a second or third AED 3 . When monotherapy fails and patients experience an unacceptable number of seizures or side effects that interfere with their normal daily activities, 'switching' AED treatment is the next most likely option in current clinical practice.
Physicians generally choose to switch patients progressively from one AED to another over several weeks. Besides the existing differences between carbamazepine and oxcarbazepine (especially carbamazepine oxidative metabolism generating an epoxide metabolite, vs. conjugation for oxcarbazepine), the analogy of chemical structures and sodium-channel blockade mechanisms suggest that they may be switched on an immediate basis (overnight). In addition, clinical experience supports the possibility of overnight switching from carbamazepine to oxcar-bazepine, but there is no consensus on the risk for increased side effects or suitability for patients intolerant or refractory to carbamazepine of such rapid conversion method [4] [5] [6] [7] .
Oxcarbazepine is a new-generation AED indicated for use as monotherapy or combination therapy in adults and children (in the US as adjunctive therapy only in children) with partial seizures, including the subtypes of simple and complex, and secondarily generalised tonic-clonic seizures (in some countries, it is also indicated for primary generalised tonic-clonic seizures). Conversion to oxcarbazepine monotherapy, both from carbamazepine and other AEDs, has been shown to be effective in improving seizure control and tolerability in controlled clinical trials and from extensive clinical experience [8] [9] [10] [11] [12] [13] . However, there are few published reports directly comparing overnight with progressive switch 14, 15 . We conducted the first randomised, open-label study to compare overnight and progressive switch to oxcarbazepine monotherapy in patients with partial seizures unsatisfactorily treated with carbamazepine monotherapy.
METHODS

Patients
Male or female outpatients aged ≥14 years with a diagnosis of partial seizures (including the subtypes of simple, complex and partial seizures evolving to secondarily generalised seizures) were recruited into the study. All patients were unsatisfactorily treated with therapeutic levels of carbamazepine monotherapy and required a switch for one or more of the following reasons:
• inability to achieve satisfactory seizure control due to dose-limiting side effects experienced with carbamazepine; • inability to adequately tolerate carbamazepine monotherapy even in the presence of acceptable seizure control; • patients who, despite achieving adequate seizure control, were prone to recurrent clinical conditions requiring treatment with drugs known to interact with carbamazepine.
Patients were not eligible if they experienced primary generalised or pseudo-seizures, had a history of status epilepticus in the 6 months prior to screening, or experienced seizures only occurring in clustered patterns (defined as serial seizures occurring within a 30-min period). Patients were also not permitted to enter the study if they had progressive lesions as shown by magnetic resonance imaging or computed tomography. Other grounds for exclusion included evidence of any medically relevant disorder likely to significantly impact the study outcome, serum sodium levels outside the normal range of local laboratories (on average 135-145 mmol/l), changes in laboratory values not considered to be directly related to carbamazepine therapy, pregnancy or lactation, a history of psychiatric disturbance within the 6 months prior to randomisation that required treatment (including suicide attempts and substance abuse), and known hypersensitivity to oxcarbazepine (patients with a history of hypersensitivity to carbamazepine were however eligible).
Tricyclic antidepressants and selective serotonin reuptake inhibitors were permitted in low doses during the study.
Study design
This was a multicentre, randomised, open-label, parallel-group study designed to assess the therapeutic equivalence of immediate (overnight) and progressive switching from carbamazepine to oxcarbazepine. The study consisted of two phases: screening and open-label treatment. Patients entered the screening phase of up to 2 months to collect data on seizure type and frequency unless these data could be obtained retrospectively from a patient diary or other document considered reliable by their physician. At the end of the screening phase, patients were randomised (1:1) to one of the two switch methods. The 2-month, open-label treatment phase was divided into two periods: switch and maintenance ( Fig. 1 ) and comprised three scheduled clinic visits: at randomisation (Visit 1), the second day after end of switch (Visit 2), and the end of the 2-month, open-label treatment phase (Visit 3). At Visit 1 (randomisation), inclusion and exclusion criteria were checked, a complete physical and neurological examination was carried out, and epilepsy history and baseline seizure frequency were gathered. Laboratory assessments were carried out at Visits 1 and 3. Seizure frequency, adverse events and treatment satisfaction were assessed at Visits 2 and 3.
Patients remained as outpatients throughout the open-label treatment phase and were advised to call their physician if any problems arose. Seizures were recorded continuously during the study using patient diaries and were classified according to the International Classification of Epileptic Seizures 16 
Treatment
Switching period
Patients assigned to an overnight switch had their carbamazepine treatment immediately replaced with oxcarbazepine at a daily dose ratio of 1:1.5 (carbamazepine: oxcarbazepine). Patients assigned to progressive switching had their carbamazepine treatment replaced with oxcarbazepine (Tolep®, non-coated tablet) at the same daily dose ratio, but on a slower basis. In both cases, replacement was done on a 'tablet by tablet' basis; for example, a 200 mg carbamazepine tablet was to be replaced by a 300 mg oxcarbazepine tablet, regardless of whether their regimen was b.i.d. or t.i.d. No dose adjustments were allowed during the switching period. Patients unable to complete the switch were withdrawn from the study. Immediate (overnight) switching could be completed on the day after randomisation. For example, a patient receiving 400 mg b.i.d. carbamazepine on Day 0 (randomisation) could be instructed to take 600 mg b.i.d. oxcarbazepine on Day 1. However, if the investigator considered that patient tolerability could be optimised by a night of sleep between the first and second oxcarbazepine dose, the first dose could be given in the evening of Day 0 instead of the scheduled carbamazepine dose, and the second oxcarbazepine dose could be given on the morning of Day 1. Therefore, Day 1 was the first day on which any patient received only oxcarbazepine.
For progressive switching, carbamazepine was replaced by oxcarbazepine every second day until total substitution was achieved, but daily dose increments of >300 mg oxcarbazepine were not allowed. For example, carbamazepine 400 mg tablets could be halved so that each 200 mg part could be substituted with a 300 mg oxcarbazepine tablet every second day. Substitution was also permitted every third day in cases where slower titration was indicated. Patients were therefore receiving carbamazepine and oxcarbazepine concomitantly until the switch was completed. The total duration of progressive switches was variable, depending on the total daily dose of carbamazepine the patient was initially receiving.
Maintenance period
Oxcarbazepine dose adjustments were allowed (as warranted by the investigator) at any time during the maintenance period, if clinically indicated.
Assessments
Efficacy variables
The primary efficacy endpoint was the individual average number of seizures per month from randomisation until study end. Secondary efficacy endpoints were the 'between-group' and 'within-group' differences in the mean of the average monthly seizure frequency before and after the switch (2 months' screening, 2 months' treatment).
Safety variables
The primary tolerability endpoint was the proportion of patients who did not experience any clinically significant adverse events during the switch period, which was defined as starting on the day of the first oxcarbazepine dose and ending one day after the last oxcarbazepine monotherapy dose was administered. Clinically significant adverse events were defined as events that were considered moderate or severe by the investigator, required specific medical intervention, or led to modification or interruption of AED therapy. The secondary tolerability endpoint was the 'between-group' difference in the proportion of patients with no clinically significant adverse events over the 2-month, open-label treatment phase as assessed at Visit 3.
Safety was assessed on the basis of adverse events, physical and neurological examinations, vital signs and laboratory tests. At the end of the switch period and at study completion, patients and physicians also performed a Global Assessment of Treatment Satisfaction by rating their satisfaction with treatment on a 4-point scale as 'poor', 'fair', 'good' or 'very good'.
Statistical analysis
The average monthly seizure frequency was calculated by dividing the number of observed seizures for a given patient by the length of the open-label treatment phase in days and multiplying by 30.5. Equivalence between the two switch methods was established by calculating the two-sided 95% confidence intervals (CI) of the 'between-group' difference of the means of the average number of seizures per month during the open-label treatment phase.
A sample size of 140 patients per group (280 total) was initially calculated to give the study 80% power to demonstrate equivalence assuming a maximum non-clinically relevant 'between-group' difference in the mean number of seizures per month of 1.0 with a standard deviation of three seizures per month, and that the observed difference between the groups would not exceed 0.3 seizures per month. In addition, a secondary analysis compared the seizure frequency within each treatment group before and after switching, using the Wilcoxon signed-rank test and between groups using the Mann-Whitney U-test.
Non-inferiority of tolerability after overnight switching was calculated by comparing the proportion of patients who did not experience clinically significant adverse events between groups. The maximum non-clinically relevant 'between-group' difference in the proportion of patients who did not experience clinically significant adverse events during the switch was set to 10%. It was hypothesised that the proportion of patients falling into this category in the progressive-switch group would not be <87% and that the observed difference between groups would not be >3.4%. A total of 140 patients were necessary to give the study 80% power and demonstrate non-inferiority of tolerability for overnight versus progressive switching (for the one-sided 95% CI to extend 6.6% from the observed 'between-group' difference).
Analyses were carried out on all patients switched to oxcarbazepine and receiving at least one dose, including those who did not complete the maintenance phase (the evaluable patient population).
RESULTS
Patient characteristics
A total of 288 patients at 41 centres in Italy were randomised to undergo a switch from carbamazepine to oxcarbazepine monotherapy. Two patients did not receive study medication. Overall, 286 patients were evaluable: 140 and 146 patients in the overnight-and progressive-switch groups, respectively. The baseline characteristics of all randomised patients are shown in Table 1 .
The baseline characteristics of the two switch groups were comparable, including seizure frequency and age. The proportion of males to females (57.1% vs. 42.9%, respectively) in the overnight-switch group was reversed in the progressive group (41.1% vs. 58.9%, respectively). The majority of patients in both switch groups (65.0%) required a switch from carbamazepine due to inadequate tolerability.
Overall, 93.4% of the patients completed the study: 94.3% (132/140) in the overnight-switch group and 92.5% (135/146) in the progressive-switch group. A total of 19 patients discontinued prematurely (3 during switch, 16 during maintenance): 10 due to adverse events, 5 due to unsatisfactory therapeutic effect, 2 due to protocol violations, and 2 patients withdrew consent. Of the 3 patients who discontinued during the switch, 1 patient in the overnight-switch group was withdrawn due to an adverse event (diffuse cutaneous eruption), 1 of the 2 patients in the progressive-switch group was withdrawn due to adverse events (memory impairment, vertigo, headache), and the other was withdrawn due to lack of efficacy. For the 16 patients who discontinued while on maintenance therapy, irrespective of the switch group, the mean (range) duration of maintenance therapy was 23.4 (1.0-54.0) days, out of a maximum of 2 months.
Study treatment
Mean (range) switch duration was 1.4 (1.0-3.0) days in the overnight group and 7.0 (2.0-16.0) days in the progressive group. Last mean daily doses of carbamazepine before switch were 786.4 and 764.4 mg in the overnight and progressive groups, respectively, and daily doses ranged from 200 to 1600 mg. Following the switch to oxcarbazepine, the mean duration of maintenance treatment was 60.9 and 58.4 days for the overnight and progressive groups, respectively. Most patients (80.8%) switching progressively had oxcarbazepine substituted for carbamazepine every 2 days. At study end, both groups of patients were receiving similar mean doses of oxcarbazepine (1186.0 and 1138.5 mg per day for the overnight and progressive groups, respectively), and the mean dose ratios of carbamazepine:oxcarbazepine were 1:1.56 (overnight group) and 1:1.55 (progressive group).
Efficacy
The difference between groups in the primary efficacy endpoint (the average monthly seizure frequency during open-label treatment) supported the equivalence of overnight and progressive switching, as shown in Table 2 . As the individual values for seizure frequency were not normally distributed (i.e. were asymmetric; Fig. 2) , median values were used to compare the efficacy of overnight and progressive switch methods in the first instance. When 8 outliers (4 patients in each group with >25 monthly seizures at any point) were excluded from the analysis, mean values also supported the equivalence of the two switching methods ( Table 2 ). The secondary analyses on the overall comparisons of before versus after switch clearly show that patients benefited significantly from both types of switching (Table 2 and Fig. 2 ). There was an overall improvement in monthly seizure frequency after switching (difference of the means from baseline = −0.94, 95% CI −2.18, 0.30). Following the switch from carbamazepine to oxcarbazepine, there was a reduction in the median monthly seizure frequency in both the overnight group (from 1.5 to 0, P = 0.0005) and To demonstrate equivalence, 95% CI values should not exceed 1.0, based on the maximum non-clinically relevant difference in the monthly number of seizures being set to 1.0. a Outliers were patients with >25 monthly seizures either at baseline or after randomisation (four patients in each group). There were four outliers in each group: three patients had >25 monthly seizures at baseline; four patients had >25 monthly seizures after randomisation; one patient had >25 monthly seizures both at baseline and after randomisation.
the progressive group (from 1.0 to 0.4, P = 0.003; Wilcoxon signed-rank test). The benefit of switching is also shown with the proportion of seizure-free patients on oxcarbazepine monotherapy. During screening, 110 patients out of 286 (38.5%) had no seizures (103/187 switching for lack of tolerability, 7/9 for need of interacting drugs). None of the 143 patients switching for unsatisfactory seizure control were previously seizure-free. The number of seizure-free patients increased from 53 (37.9%) to 71 (50.7%) in the overnight group after switching (P = 0.002) and from 57 (39.0%) to 72 (49.3%) in the progressive group (P = 0.010; McNemar's test), respectively. Again, the overnight switch seems to offer a little better seizure control.
Furthermore, there was no significant difference between male and female patients in median monthly seizure frequency (0.21 vs. 0.23, P = 0.554). Thus, the apparent imbalance in the gender distribution of the two switching types should not be a concern in the efficacy comparisons.
Of the 143 patients switching due to unsatisfactory seizure control on carbamazepine, 46.1% showed a decrease in monthly seizure frequency of ≥50%. There was a potential trend favouring overnight switching for these patients, with median monthly seizure reductions of 1.7 (from 3.3 at baseline) in the overnight group versus 1.3 (from 3.9 at baseline) in the progressive group (P < 0.05; Fig. 3 ). In addition, 50.7% of patients who switched overnight experienced a decrease of ≥50% in monthly seizure frequency, compared with 41.4% of patients who switched progressively. Patients switching due to poor tolerability on carbamazepine also experienced significant improvements in seizure frequency after switching to oxcarbazepine: P = 0.01 and P = 0.05 in the overnight and progressive groups, respectively.
Safety and tolerability
A total of 90.0 and 92.5% of patients experienced no clinically significant adverse events during switching in the overnight and progressive groups, respectively. The 95% CI of the 'between-group' difference did not exceed 10% (difference of 2.5; 95% CI −4.1, 9.0) and therefore demonstrated the non-inferiority of overnight-and progressive-switch methods.
Where switches were carried out due to poor tolerability with carbamazepine (n = 187), 88.8 and 90.8% of patients were judged not to have experienced clinically significant adverse events in the overnight and progressive groups, respectively (difference of 2.1; 95% CI −6.7, 10.8). In addition, for the treatment phase as a whole (switch and maintenance), 80.7 and 82.9% of physicians rated their patients not to have experienced such events with oxcarbazepine for the overnight and progressive groups, respectively (difference of 2.2; 95% CI −6.8, 11.1). Although the study was not powered to demonstrate non-inferiority in these secondary analyses, 95% CI values were close to the predetermined 10% limit. Overall, 14 patients (10.0%) who switched overnight and 11 patients (7.5%) who switched progressively were judged to have experienced clinically significant adverse events. Of these patients, 10/14 and 9/11, respectively, had experienced poor tolerability with carbamazepine. In the subpopulation switching from carbamazepine due to poor tolerability, carbamazepine-related adverse events were completely or partially resolved in nearly 90% of patients (Fig. 4) . There was no significant difference between the proportions of male and female patients reported to have experienced clinically significant adverse events at the end of switch (8.6% vs. 8.9%, P = 0.921). For the study as a whole, adverse events were in line with the known tolerability and safety profiles of oxcarbazepine (Table 3) . During the switch period, the most frequently reported treatment-emergent adverse events judged as clinically significant (>1 patient in either group) were nausea, headache, vertigo, somnolence and paresthesia (Table 3) . Overall, 10 patients (7.1%) who switched overnight and 9 patients (6.2%) who switched progressively discontinued the study due to an adverse event. Four overnight-switch patients and two progressive-switch patients experienced serious adverse events during the open-label treatment phase. In the overnight-switch group, these serious events (all n = 1) were allergic dermatitis (patient discontinued), fever (resolved after 8 days), headache (with aggravation of seizures) and hyponatraemia (resolved after 10 days, patient discontinued). This was the only case of hyponatraemia and occurred in a patient undergoing an overnight switch; serum sodium levels for this patient were 135 mmol/l at baseline and 136 mmol/l at study end. In the progressive-switch group, the serious adverse events were aggravation of seizures (n = 1) and partial seizure associated with fracture of the arm (n = 1, patient discontinued treatment). There were no important changes in the mean values of haematological and biochemical laboratory tests. A small number of abnormal laboratory values (increases) were recorded during treatment with oxcarbazepine (blood urea nitrogen, aspartate aminotransferase, gamma-glutamyl transpeptidase, alkaline phosphatase, calcium and potassium). There were no significant differences in the pattern or extent of laboratory values between the two switch methods.
Overall treatment satisfaction
At the end of the switch period, 90.7 and 87.0% of physicians rated overall treatment satisfaction for overnight and progressive switching to be 'good' or 'very good', respectively. Furthermore, 88.6 and 85.6% of patients also rated their overall treatment satisfaction for overnight and progressive switching to be 'good' or 'very good', respectively.
DISCUSSION
This study demonstrates the validity and clinical feasibility of two methods of switching (overnight and progressive) from carbamazepine monotherapy to oxcarbazepine monotherapy in patients with partial seizures. To our knowledge, it is the first study to directly and systematically compare two methods of switching from carbamazepine to oxcarbazepine. The difference between groups in the average monthly number of seizures after the switch confirms that there is no significant difference in the utility of these switch methods. This conclusion is supported by the accumulating evidence coming from all analyses done on medians and excluding the outliers, which were done in an attempt to overcome the distributional problems of the primary variable. The main relevance of these findings for daily practice is that oxcarbazepine allows flexibility in tailoring treatment switch strategies at the individual patient level. Furthermore, overnight switch from carbamazepine monotherapy to oxcarbazepine monotherapy may be most appropriate for patients who experience poor seizure control on carbamazepine, as this subgroup of patients appeared to benefit more from overnight switching in our study.
The difference in seizure frequency after switch, shows the overall benefit of switching to oxcarbazepine monotherapy for patients with partial seizures who are unsatisfactorily treated with carbamazepine monotherapy, both in terms of efficacy and safety. Switching from carbamazepine to oxcarbazepine monotherapy was associated with a better response, as there was a decrease in average monthly seizure frequency and an increase in the percentage of seizure-free patients. Seizure control was increased both in patients previously uncontrolled on or intolerant to previous carbamazepine therapy. Tolerability was improved after switch overall with improvement or resolution of previous side effects on carbamazepine in more than 88% of cases.
Guidelines and data-based reviews confirm that an overnight switch is suitable for patients who are receiving carbamazepine monotherapy, but are intolerant of its side effects or experience inadequate seizure control [5] [6] [7] 18, 19 . However, it has been noted that when patients receive ≥800 mg/day carbamazepine, they may experience increased side effects during rapid switching. Variation in the degree of carbamazepine autoinduction between patients is thought to be responsible for this effect and can lead to widely different serum drug levels from the same oral dose 6 . Although daily doses of carbamazepine ranged from 200 to 1600 mg in the current study, and some patients taking controlled-release carbamazepine received oxcarbazepine concomitantly during immediate switch, the high proportion (≥90%) of patients who did not experience clinically significant adverse events during the switch period supported the non-inferiority of overnight switching. There were no safety concerns associated with either overnight-or progressive-switch methods.
Monotherapy studies with active comparators have demonstrated improved tolerability and equivalent efficacy of oxcarbazepine compared with carbamazepine and phenytoin, and similar tolerability and efficacy compared with valproate 4, [20] [21] [22] . These studies have established that oxcarbazepine is a valuable first-choice treatment option for initiating therapy in newly diagnosed patients with partial seizures. However, the current study underlines that oxcarbazepine may also provide effective seizure control and is well tolerated in patients in which a previous monotherapy with carbamazepine has failed.
Oxcarbazepine was well tolerated throughout the open-label treatment phase regardless of the switch method. Approximately 90% of patients who switched from carbamazepine due to tolerability problems did not experience these problems, fully or in part, on oxcarbazepine monotherapy. Ten patients (7.1%) in the overnight group and nine patients (6.2%) in the progressive group experienced adverse events that led to discontinuation from the study. As expected, the discontinuation events were mainly those affecting the central nervous system, with the exception of one case each of hyponatraemia, pruritis and dermatitis. The proportion of discontinuations compared favourably with published studies of patients initiating or switching to oxcarbazepine monotherapy, where 3.5-17.4% of patients discontinued due to adverse events 12, 13, 20, 22, 23 .
The clinical efficacy and good tolerability observed during the overnight switches in this study suggest that future investigations could examine overnight switching in patients receiving carbamazepine as combination therapy. Cost-benefit analysis should also be considered, since overnight switching potentially involves less monitoring and less cost than more protracted methods of treatment conversion.
In conclusion, for patients who are unsatisfactorily treated with carbamazepine monotherapy, overnight switch to oxcarbazepine monotherapy was as effective and well tolerated as a progressive switch. Therefore, switch to oxcarbazepine is easy to perform with full flexibility in individualising patient care. Overall, patients benefited from switching to oxcarbazepine monotherapy independently of the switch method used, with respect to either safety, tolerability, efficacy or to all combined.
